OB
OBIO.O
—
NASDAQ
Advanced Medical Equipment & Technology
Orchestra Biomed Holdings Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-154,7 %
ROE
-83,2 %
Net margin
-157,4 %
Debt / equity
0,23
Beta
—
52w range
—
Volume
1,1k
Day range
$3,94–$4,03
Prev close
$3,95
Open
$3,95
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Orchestra Biomed Holdings Inc develops and commercializes advanced medical equipment and technology, primarily focused on diagnostic and therapeutic solutions for healthcare providers.
Business. Orchestra Biomed Holdings Inc (OBIO.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm primarily engages in the sale of advanced medical equipment and technology products. It is listed on the NASDAQ stock exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY8 analysts
7 buy1 hold0 sell
Avg 12m price target11,17
Analyst recommendations
8 analysts · consensus BuyBuy7
Hold1
Sell0
12-month price target
11,17
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability→
-83,2 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to OBIO.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Orchestra Biomed Holdings Inc (OBIO.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm primarily engages in the sale of advanced medical equipment and technology products. It is listed on the NASDAQ stock exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
AI synthesis
GENERATEDOrchestra Biomed's capital structure is characterized by a low debt-to-equity ratio of 0.23, indicating a conservative leverage profile. The company holds $34.69 million in cash and equivalents, which is significantly higher than its $14.27 million in long-term debt, supporting a current ratio of 6.45 and suggesting strong short-term liquidity. However, the company reported negative operating and free cash flows of -$48.96 million and -$52.86 million, respectively, indicating ongoing cash burn despite its strong cash reserves.
Profitability metrics are weak, with a return on equity of -83.15% and a return on assets of -45.88%, both far below the industry median for Advanced Medical Equipment & Technology firms. The company reported a net loss of $52.70 million on $33.48 million in revenue, with a gross profit margin of 99.43% but an operating margin of -154.73%, reflecting high operating expenses relative to revenue.
The company's revenue is concentrated in a single business segment, as disclosed in its latest financials, with no geographic breakdown provided. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment and technology sector.
Looking ahead, the company is expected to continue experiencing revenue contraction in the current fiscal year, with no clear signs of improvement in the next fiscal year. The negative operating cash flow and high cash burn rate suggest the company may need to raise additional capital or reduce expenses to sustain operations.
Risk factors include the company's reliance on a single product line and the potential for increased competition in the advanced medical equipment market. The risk assessment indicates low dilution and liquidity risk, but the absence of positive cash flow remains a concern. No immediate dilution threats were identified in recent filings, and the company has not issued new shares in the past 12 months.
Recent events include the release of Q4 financial results, which showed continued losses and declining cash reserves. The company has not announced any major product launches or strategic partnerships in the past six months, and no significant regulatory changes have been reported that would directly impact its operations.
Key takeaways
- Orchestra Biomed is operating at a significant loss with negative operating and free cash flows.
- The company has a strong liquidity position but is burning through cash at a high rate.
- Profitability metrics are far below industry medians, indicating operational inefficiencies.
- The company's business is concentrated in a single segment, increasing exposure to market-specific risks.
- Analysts have a cautiously optimistic outlook, with a mean price target of $11.17.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$3,65
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$63.4M
Net cashⓘ
$20.4M
Current ratioⓘ
6.5
Debt / equityⓘ
0.2
ROAⓘ
-45.9%
ROEⓘ
-83.2%
Cash conversionⓘ
93.0%
CapEx / revenueⓘ
-1.5%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships11 disclosed relationships · 4 types · extracted from filings & disclosures
Customers1
Haemonetics CORP/MASSHAE.OCustomer95%Source ↗
Partners1
Medtronic PLCMDT.OPartner98%Source ↗
Vendors2
Integer Holdings CorpITGR.OVendor95%Source ↗
SANMINA CORPORATIONSANM.OVendor95%Source ↗
Subsidiaries7
EX21:0e157ade8cc8EX21:0e157ade8cc8Subsidiarie97%
EX21:233d8cb11689EX21:233d8cb11689Subsidiarie97%
EX21:33e0173ea32aEX21:33e0173ea32aSubsidiarie97%
EX21:47c2e105d35aEX21:47c2e105d35aSubsidiarie97%
EX21:58afc6786aecEX21:58afc6786aecSubsidiarie97%
EX21:70374f1f8514EX21:70374f1f8514Subsidiarie97%
EX21:ebe6249a9fd7EX21:ebe6249a9fd7Subsidiarie97%
Supply chain
Vendors → OBIO ↔ Partners → Customers · click any node to drill
4 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs OBIO · multiples and returns
TM
TMO—
Thermo Fisher Scientific Inc
$574,03
214,1B USDP/E
29,4x
— vs self
Div yield
0,3 %
— vs self
ROE
12,9 %
+96,1 vs self
DH
DHR—
Danaher Corp
$197,50
140,1B USDP/E
38,2x
— vs self
Div yield
—
— vs self
ROE
6,9 %
+90,0 vs self
GE
GEHC—
GE HEALTHCARE TECHNOLOGIES INC.
$69,72
31,9B USDP/E
13,6x
— vs self
Div yield
0,2 %
— vs self
ROE
19,5 %
+102,7 vs self
PH
PHG—
PHG
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BS
BSX—
Boston Scientific Corp
$48,54
72,6B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
IS
ISRG—
INTUITIVE SURGICAL, INC.
$376,00
133,2B USDP/E
287,7x
— vs self
Div yield
—
— vs self
ROE
3,6 %
+86,7 vs self
A
A—
Agilent Technologies Inc
$139,80
39,6B USDP/E
29,0x
— vs self
Div yield
0,8 %
— vs self
ROE
19,3 %
+102,5 vs self
EW
EW—
Edwards Lifesciences Corp
$88,82
51,6B USDP/E
44,3x
— vs self
Div yield
—
— vs self
ROE
10,4 %
+93,5 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-1,76
Predicted surprise
+0,00
Beat probability
45 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-04 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,76 |
| Revenue | —no estimate | —no estimate | 774,200 USD |
| Operating income | —no estimate | —no estimate | -98,8M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy1
Buy6
Hold1
Sell0
Strong sell0
12-month price target$11,17 · Median $11,00
Low $9,00High $15,00
Operating income · consensus-98,8M USD
EPS surprise
+37,7 %
reported vs consensus · beat
Revenue surprise
+4 224,7 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$9,00
Mean$11,17
Median$11,00
High$15,00
Spot$3,65
+205.9 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-154,7 %Bottom quartile
Net Margin-157,4 %Bottom quartile
ROE-83,2 %Bottom quartile
Capex / Rev-1,5 %Above median
D/E0,23Below median
Cash Conv0,93Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 1 031 095 sh1 exercises · 6 grants7 insiders
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 277 @ $4,04grant · 2026-06-23
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 277 @ $4,04grant · 2026-06-23
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 277 @ $4,04grant · 2026-06-23
- Director · Stock Option (Right to Buy) → Common StockAcquired 42 553 @ $4,04grant · 2026-06-23
- Director · Stock Option (Right to Buy) → Common StockAcquired 42 553 @ $4,04grant · 2026-06-23
- 10% owner · Pre-Funded Warrants (Right to Buy) → Common StockDisposed 1 250 032 @ $0,00exercise · 2026-04-27
- Principal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 70 000 @ $3,82grant · 2026-02-12
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- Orchestra Biomed Holdings Inc Market data — financials · 2026-05-28
- Orchestra Biomed Holdings Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2025-12-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Net buying6 buys · 2 sellsnet $143K11 insiders · last 365d
- Director · Common StockOther 3 510 · 2026-06-24
- Director · Common Stock, par value $0.0001 per shareOther 3 510 · 2026-06-24
- Director · Common StockOther 3 784 · 2026-06-24
- Director · Common StockOther 4 261 · 2026-06-24
- Director · Common Stock, par value $0.0001 per share ("Common Stock")Other 17 327 · 2026-06-23
- Director · Common Stock, par value $0.0001 per share ("Common Stock")Other 17 327 · 2026-06-23
- Director · Common Stock, par value $0.0001 per share ("Common Stock")Other 17 327 · 2026-06-23
- Director · Common Stock, par value $0.0001 per share ("Common Stock")Other 34 653 · 2026-06-23
- Chief Financial Officer · Common Stock, par value $0.0001 per shareOther 36 352 @ $4,02$146K · 2026-06-10
- Director, See Remarks · Common StockOther 3 283 @ $4,02$13K · 2026-06-10
- Director, See Remarks · Common Stock, par value $0.0001 per share ("Common Stock")Other 3 283 @ $4,02$13K · 2026-06-10
- Director, See Remarks · Common Stock, par value $0.0001 per shareSold 15 000 @ $3,87$58K · 2026-06-01
- Director, See Remarks · Common Stock, par value $0.0001 per share ("Common Stock")Bought 5 000 @ $3,83$19K · 2026-06-01
- Chief Financial Officer · Common Stock, par value $0.0001 per shareOther 3 076 @ $3,98$12K · 2026-05-28
- Director, See Remarks · Common Stock, par value $0.0001 per shareOther 4 925 @ $3,98$20K · 2026-05-28
- Director · Common Stock, par value $0.0001 per shareBought 665 @ $3,75$2K · 2026-05-18
- Director, See Remarks · Common Stock, par value $0.0001 per share ("Common Stock")Bought 5 000 @ $3,77$19K · 2026-05-15
- Director · Common Stock, par value $0.0001 per shareBought 8 971 @ $3,90$35K · 2026-05-15
- Director · Common Stock, par value $0.0001 per shareBought 20 000 @ $4,13$83K · 2026-05-14
- 10% owner · Common StockOther 1 250 032 @ $0,00$125 · 2026-04-27
- 10% owner · Common StockSold 32 @ $4,13$132 · 2026-04-27
- Director, See Remarks · Common Stock, par value $0.0001 per share ("Common Stock")Other 32 438 @ $4,57$148K · 2026-03-25
- Director, See Remarks · Common Stock, par value $0.0001 per shareOther 33 317 @ $4,57$152K · 2026-03-25
- Principal Accounting Officer · Common Stock, par value $0.0001 per share ("Common Stock")Other 241 @ $4,57$1K · 2026-03-25
- Director, See Remarks · Common Stock, par value $0.0001 per share ("Common Stock")Bought 10 000 @ $4,29$43K · 2026-03-13
Short positioning
2.6Mshares short+16.4% vs prior
10.86days to cover
23.6%short of daily vol
1.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
OBIO.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorCustomersPartnersVendorsSubsidiaries
Evidence & claims
From filings & derived data- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 35.9%Derived (calculated)
- Net margin (FY 2025-12-31): -157.4%Derived (calculated)
- Return on assets (FY 2025-12-31): -45.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 6.45xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 69.2%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 55.8%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -6.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 33.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 33.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 13.6%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 3.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 19.4%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 1,169.2%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 50.8%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 19.1%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- Revenue (annual): USD 33.48MSEC XBRL filing
- Net income (annual): USD -52.7MSEC XBRL filing
- Capex (annual): USD 489KSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
- Cost of revenue (annual): USD 190KSEC XBRL filing
- Long-term debt (annual): USD 15MSEC XBRL filing
- Cash & equivalents (annual): USD 34.69MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-24 00:00 UTCINSIDER18 insider transactions — 2026-06 · net sell $211k 5 derivative
2026-06-24INSIDERMack John Prosper transacted 3.5k sh — Director
2026-06-24INSIDERCleary Chris transacted 3.5k sh Common Stock, par value $0.0001 per share — Director
2026-06-24INSIDERPacitti David transacted 3.8k sh — Director
2026-06-24INSIDERFain Eric S transacted 4.3k sh — Director
2026-06-23INSIDERConnealy Pamela Ann transacted 17.3k sh Common Stock, par value $0.0001 per share ("Common Stock") — Director
2026-06-23INSIDERFain Eric S transacted 17.3k sh Common Stock, par value $0.0001 per share ("Common Stock") — Director
2026-06-23INSIDERPacitti David transacted 17.3k sh Common Stock, par value $0.0001 per share ("Common Stock") — Director
2026-06-23INSIDERMack John Prosper transacted 34.7k sh Common Stock, par value $0.0001 per share ("Common Stock") — Director
2026-06-23INSIDERConnealy Pamela Ann acquired 21.3k sh Stock Option (Right to Buy) — Director
2026-06-23INSIDERPacitti David acquired 21.3k sh Stock Option (Right to Buy) — Director
2026-06-23INSIDERCleary Chris acquired 42.6k sh Stock Option (Right to Buy) — Director
2026-06-23INSIDERAryeh Jason acquired 42.6k sh Stock Option (Right to Buy) — Director
2026-06-23INSIDERFain Eric S acquired 21.3k sh Stock Option (Right to Buy) — Director
2026-06-10INSIDERTaylor Andrew Lawrence transacted 36.4k sh Common Stock, par value $0.0001 per share — Chief Financial Officer ~$146k
2026-06-10INSIDERHochman David P transacted 3.3k sh — Director, See Remarks ~$13k
2026-06-01INSIDERSherman Darren sold 15.0k sh Common Stock, par value $0.0001 per share — Director, See Remarks ~$58k
2026-06-01INSIDERHochman David P bought 5.0k sh Common Stock, par value $0.0001 per share ("Common Stock") — Director, See Remarks ~$19k
2026-05-28 00:00 UTCINSIDER6 insider transactions — 2026-05 · net buy $107k
2026-05-28INSIDERTaylor Andrew Lawrence transacted 3.1k sh Common Stock, par value $0.0001 per share — Chief Financial Officer ~$12k
2026-05-28INSIDERSherman Darren transacted 4.9k sh Common Stock, par value $0.0001 per share — Director, See Remarks ~$20k
2026-05-18INSIDERAryeh Jason bought 665 sh Common Stock, par value $0.0001 per share — Director ~$2k
2026-05-15INSIDERHochman David P bought 5.0k sh Common Stock, par value $0.0001 per share ("Common Stock") — Director, See Remarks ~$19k
2026-05-15INSIDERAryeh Jason bought 9.0k sh Common Stock, par value $0.0001 per share — Director ~$35k
2026-05-14INSIDERFain Eric S bought 20.0k sh Common Stock, par value $0.0001 per share — Director ~$83k
2026-04-27 00:00 UTCINSIDER3 insider transactions — 2026-04 1 derivative
2026-04-27INSIDERRTW INVESTMENTS, LP transacted 1.25M sh — 10% owner ~$0k
2026-04-27INSIDERRTW INVESTMENTS, LP sold 32 sh — 10% owner ~$0k
2026-04-27INSIDERRTW INVESTMENTS, LP disposed of 1.25M sh Pre-Funded Warrants (Right to Buy) — 10% owner
2026-03-25 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $259k
2026-03-25INSIDERHochman David P transacted 32.4k sh Common Stock, par value $0.0001 per share ("Common Stock") — Director, See Remarks ~$148k
2026-03-25INSIDERSherman Darren transacted 33.3k sh Common Stock, par value $0.0001 per share — Director, See Remarks ~$152k
2026-03-25INSIDERAiello Joshua transacted 241 sh Common Stock, par value $0.0001 per share ("Common Stock") — Principal Accounting Officer ~$1k
2026-03-13INSIDERHochman David P bought 10.0k sh Common Stock, par value $0.0001 per share ("Common Stock") — Director, See Remarks ~$43k
Showing the 40 most recent of 50 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage